An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors IMPAX Laboratories
- 25 Apr 2015 Results of pooled analysis of 7 phase II and III studies presented at the 67th Annual Meeting of the American Academy of Neurology.
- 24 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Aug 2011 New trial record